Silymarin in multiple Sclerosis

INTERVENTION: Control group: Placebo tablets, 140 mg, 3 times a day, for 6 months, orally Intervention 1: Intervention group: Silymarin tablets, 140 mg, 3 times a day, for 6 months, orally. Intervention 2: Control group: Placebo tablets, 140 mg, 3 times a day, for 6 months, orally. Intervention group: Silymarin tablets, 140 mg, 3 times a day, for 6 months, orally Treatment ‐ Drugs CONDITION: Therapeutic effect of silymarin. PRIMARY OUTCOME: Serum interferon gamma. Timepoint: 2 months before the intervention, 6 months after the intervention. Method of measurement: ELISA. Serum interleukin level 10. Timepoint: 2 months before the intervention, 6 months after the intervention. Method of measurement: ELISA. Serum interleukin level 17. Timepoint: 2 months before the intervention, 6 months after the intervention. Method of measurement: ELISA. Serum interleukin level 23. Timepoint: 2 months before the intervention, 6 months after the intervention. Method of measurement: ELISA. Serum interleukin level 35. Timepoint: 2 months before the intervention, 6 months after the intervention. Method of measurement: ELISA. Serum level of tumor growth factor beta. Timepoint: 2 months before the intervention, 6 months after the intervention. Method of measurement: ELISA. INCLUSION CRITERIA: People with multiple sclerosis who go to Kashani hospital in Isfahan. Patients taking CinnoVex for less than 1 year.